Abstract
Objective: The aim was to determine the activity of serum PAI 1 in men with prostate cancer and its relationship with hypertension characteristics. Design and method: 39 men (median age 63.8 [52.7; 70.5]) with prostate cancer were enrolled. Serum PAI 1 activity levels were determined using a modified colorimetric method of plasminogen activator determination. We examined the association of plasma PAI 1 with incident hypertension by multivariate logistic regression, adjusting for age, obesity, lipids, fasting glucose, kidney function, inflammation, and follow-up years. Results: Arterial hypertension was detected in 26 (66.7 %) patients with prostate adenocarcinoma. The median PAI 1 activity level in patients with prostate cancer was 77.95 [64.72; 92.12] U/mL, in the control group – 64.54 [52.35;85.45] U/mL (p< 0.05). The PAI 1 activity level correlated with diastolic blood pressure (R = 0.69, p < 0.001), duration of prostate adenocarcinoma (R = 0.42, p < 0.001), and testosterone level (R = 0.60, p < 0.001). Higher level of log-transformed PAI 1 was associated with 1.29-fold increased risk of hypertension [odds ratio (OR) (95% confidence interval): 1.29 (1.09–1.53)]. Conclusions: Men with prostate cancer are characterized by increased levels of PAI 1 associated with hypertension. More research is needed to establish a relationship between PAI 1 and hypertension in men with prostate cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
